UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Health-Related Quality Of Life In Metastatic Castration-Resistant Prostate Cancer: A Critical Literature Review

Value in health, 2015-05, Vol.18 (3), p.A211-A211

2015

Volltextzugriff (PDF)

631P Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)

Annals of oncology, 2020-09, Vol.31, p.S520-S521

2020

Volltextzugriff (PDF)

1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study

Annals of oncology, 2023-10, Vol.34, p.S984-S984

2023

Volltextzugriff (PDF)

Hydrodynamic mobilities in a bar-chain polymer model

Journal of non-Newtonian fluid mechanics, 2022-04, Vol.302, p.104752, Article 104752

Phillies, George D.J.

2022

Volltextzugriff (PDF)

1827P Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2023-10, Vol.34, p.S989-S990

2023

Volltextzugriff (PDF)

616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis

Annals of oncology, 2021-09, Vol.32, p.S655-S656

2021

Volltextzugriff (PDF)

1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2022-09, Vol.33, p.S1221

2022

Volltextzugriff (PDF)

LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

Annals of oncology, 2022-09, Vol.33, p.S1433

2022

Volltextzugriff (PDF)

1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1165-S1166

2022

Volltextzugriff (PDF)

593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2021-09, Vol.32, p.S640-S641

2021

Volltextzugriff (PDF)

Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study

European urology, 2022-02, Vol.81, p.S771-S772

2022

Volltextzugriff (PDF)

622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)

Annals of oncology, 2021-09, Vol.32, p.S660-S660

2021

Volltextzugriff (PDF)

609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019

Annals of oncology, 2021-09, Vol.32, p.S650-S651

2021

Volltextzugriff (PDF)

621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study

Annals of oncology, 2021-09, Vol.32, p.S659-S659

2021

Volltextzugriff (PDF)

1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1182-S1183

2022

Volltextzugriff (PDF)

1384P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019

Annals of oncology, 2022-09, Vol.33, p.S1175-S1176

2022

Volltextzugriff (PDF)

923P Molecular classification of cancers of unknown primary expands and refines treatment options

Annals of oncology, 2022-09, Vol.33, p.S968-S969

2022

Volltextzugriff (PDF)

980P - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)

Annals of oncology, 2019-10, Vol.30, p.v397-v398

2019

Volltextzugriff (PDF)

Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)

Annals of oncology, 2019-10, Vol.30, p.v397-v398

2019

Volltextzugriff (PDF)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

Annals of oncology, 2018-10, Vol.29 (10), p.2098-2104

2018

Volltextzugriff (PDF)

598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2021-09, Vol.32, p.S643-S644

2021

Volltextzugriff (PDF)

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science

Prostate cancer and prostatic diseases, 2016-06, Vol.19 (2), p.111-121

2016

Volltextzugriff (PDF)

Diffusion on a molecular scale as observed using PGSE NMR

Concepts in magnetic resonance. Part A, Bridging education and research, 2015-01, Vol.44 (1), p.1-15

Phillies, George D.J.

2015

Volltextzugriff (PDF)

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e281-e281

2021

Volltextzugriff (PDF)

Interpretation of fluorescence correlation spectra of biopolymer solutions

Biopolymers, 2016-05, Vol.105 (5), p.260-266

2016

Volltextzugriff (PDF)

1 – 25 von 742

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(613)
Mit Volltextzugriff
(648)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(485)
Life Sciences & Biomedicine
(236)
Physical Sciences
(186)
Biological And Medical Sciences
(111)
Humans
(111)
Exact Sciences And Technology
(105)
Technology
(98)
Chemistry
(95)
Physics
(88)
Animals
(87)
Fundamental And Applied Biological Sciences. Psychology
(72)
Applied Sciences
(68)
Male
(66)
Female
(65)
Chemistry, Physical
(58)
Engineering
(57)
Biochemistry & Molecular Biology
(44)
Physicochemistry Of Polymers
(42)
Medical Sciences
(40)
Organic Polymers
(36)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Health-Related Quality Of Life In Metastatic Castration-Resistant Prostate Cancer: A Critical Literature Review

631P Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)

1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study

Hydrodynamic mobilities in a bar-chain polymer model

1827P Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)

616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis

1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)

593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study

622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)

609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019

621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study

1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

1384P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019

923P Molecular classification of cancers of unknown primary expands and refines treatment options

980P - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)

Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science

Diffusion on a molecular scale as observed using PGSE NMR

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer

Interpretation of fluorescence correlation spectra of biopolymer solutions

Suchergebnisse filtern